TransMedics Earnings Call Highlights Record Growth
TransMedics (TMDX) reported Q3 2026 revenue of $203M, up 41% YoY, with strong growth in liver and heart transplants. Revenue guidance raised to $764M-$774M. Margins improved excluding PAD Aviation. International expansion and clinical studies progress noted.



